Nucleo

Oncology care relies on CT scan analysis such as tumor lesion sizing, body composition and sarcopenia assessment, and lesion classification, which the page implies is traditionally done through manual segmentation. Manual segmentation is time consuming and the page positions Nucleo's automated approach against it, citing a speed multiple over manual methods. The page does not specify who performs this manual work today (radiologists, technicians) or quantify the cost in time or money beyond the comparative speed claim.

Nucleo provides AI technology that automates CT scan analysis for oncology, covering three use cases: body composition and sarcopenia assessment (automatic detection and quantification of fat and muscle mass), tumor lesion sizing (precise and consistent measurement of lesions), and target vs non-target lesion classification (automated classification according to RECIST criteria, a standard oncology response evaluation framework). The site claims the tool is faster than manual segmentation and reports a percentage agreement rate between Nucleo and expert assessments, though the exact figures are not given in the scraped text. It says the company works with hospitals in the US and worldwide and that its technology is powered by unnamed 'industry leaders.'